# Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors

> **NCT02810600** · — · COMPLETED · sponsor: **Centre de recherche du Centre hospitalier universitaire de Sherbrooke** · enrollment: 2120 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **OTHER:** Gallium-68 DOTA TATE PET scan

## Key facts

- **NCT ID:** NCT02810600
- **Lead sponsor:** Centre de recherche du Centre hospitalier universitaire de Sherbrooke
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-08
- **Primary completion:** 2020-01-01
- **Final completion:** 2020-05-29
- **Target enrollment:** 2120 (ACTUAL)
- **Last updated:** 2021-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02810600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02810600, "Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02810600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*